DURHAM, N.C.--(BUSINESS WIRE)--North Carolina-based CRO, PharPoint Research, today announced their award from Otologic Pharmaceuticals for a full service, Phase I clinical trial assessing the safety, tolerability, and pharmacokinetic profile of agents in the treatment of hearing loss.
“Hearing loss is the third most common physical ailment behind arthritis and heart disease,” noted Audra McRae, PharPoint’s Chief Operating Officer. “Using our team’s experience we are excited to work on a product that potentially eases the troubles for those affected by hearing loss.”
Despite efforts to protect and preserve hearing, nearly 9 million Americans suffer from some degree of hearing damage caused by noise-induced hearing loss (NIHL). There is a short timeframe to minimize the damage caused by a NIHL and this clinical program seeks to prevent permanent hearing damage through an oral regimen taken during the initial days after the noise trauma.
Otologic selected PharPoint Research for this initiative based on the organization’s extensive experience in Phase I trials, as well as their flexible and responsive management approach, tailored specifically to the trials’ needs. Recruitment for the study is expected to begin in the third quarter of 2014.
About PharPoint Research
PharPoint Research, Inc. is a pharmaceutical development service provider specializing in project management, clinical monitoring, data management and biostatistics. Our staff is highly experienced and includes some of the most talented professionals in the industry. PharPoint Research understands the importance of responsiveness and timely deliverables with exceptional quality. We pride ourselves on maintaining an excellent repeat client rate and the ability to deliver custom solutions to our clients’ clinical trial needs. Founded in 2005, PharPoint Research currently has offices in Durham and Wilmington, NC. For more information, visit www.pharpoint.com.